274 related articles for article (PubMed ID: 31132749)
1. Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir.
Liu B; Zhang W; Zhang H
Curr Opin Virol; 2019 Oct; 38():21-30. PubMed ID: 31132749
[TBL] [Abstract][Full Text] [Related]
2. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
3. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
Yang H; Wallace Z; Dorrell L
Front Immunol; 2018; 9():2861. PubMed ID: 30564246
[TBL] [Abstract][Full Text] [Related]
5. Advances in Developing CAR T-Cell Therapy for HIV Cure.
Qi J; Ding C; Jiang X; Gao Y
Front Immunol; 2020; 11():361. PubMed ID: 32210965
[TBL] [Abstract][Full Text] [Related]
6. Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy.
Mao Y; Zhao C; Zheng P; Zhang X; Xu J
Immunotherapy; 2021 Feb; 13(2):177-184. PubMed ID: 33225803
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a Novel Humanized Mouse Model To Investigate
Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
[TBL] [Abstract][Full Text] [Related]
8. CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.
Kim GB; Hege K; Riley JL
Front Immunol; 2019; 10():2310. PubMed ID: 31611880
[TBL] [Abstract][Full Text] [Related]
9. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
[TBL] [Abstract][Full Text] [Related]
10. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1.
Liu B; Zhang W; Xia B; Jing S; Du Y; Zou F; Li R; Lu L; Chen S; Li Y; Hu Q; Lin Y; Zhang Y; He Z; Zhang X; Chen X; Peng T; Tang X; Cai W; Pan T; Li L; Zhang H
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375315
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor T-cell approaches to HIV cure.
Kuhlmann AS; Peterson CW; Kiem HP
Curr Opin HIV AIDS; 2018 Sep; 13(5):446-453. PubMed ID: 29878913
[TBL] [Abstract][Full Text] [Related]
13. HIV-Resistant and HIV-Specific CAR-Modified CD4
Maldini CR; Gayout K; Leibman RS; Dopkin DL; Mills JP; Shan X; Glover JA; Riley JL
Mol Ther; 2020 Jul; 28(7):1585-1599. PubMed ID: 32454027
[TBL] [Abstract][Full Text] [Related]
14. False-Positive Results for Human Immunodeficiency Virus Type 1 Nucleic Acid Amplification Testing in Chimeric Antigen Receptor T Cell Therapy.
Hauser JR; Hong H; Babady NE; Papanicolaou GA; Tang YW
J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31694968
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type 1 (HIV-1) antigen secretion by latently infected resting CD4+ T lymphocytes from HIV-1-infected individuals.
Fondere JM; Petitjean G; Huguet MF; Salhi SL; Baillat V; Macura-Biegun A; Becquart P; Reynes J; Vendrell JP
J Virol; 2004 Oct; 78(19):10536-42. PubMed ID: 15367620
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV.
Iwamoto N; Patel B; Song K; Mason R; Bolivar-Wagers S; Bergamaschi C; Pavlakis GN; Berger E; Roederer M
PLoS One; 2021; 16(3):e0248973. PubMed ID: 33752225
[TBL] [Abstract][Full Text] [Related]
17. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
[TBL] [Abstract][Full Text] [Related]
18. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.
Deeks SG; Wagner B; Anton PA; Mitsuyasu RT; Scadden DT; Huang C; Macken C; Richman DD; Christopherson C; June CH; Lazar R; Broad DF; Jalali S; Hege KM
Mol Ther; 2002 Jun; 5(6):788-97. PubMed ID: 12027564
[TBL] [Abstract][Full Text] [Related]
19. DC-based immunotherapy as strategy to purge the HIV reservoir?
Søgaard OS
EBioMedicine; 2019 May; 43():16-17. PubMed ID: 30981650
[No Abstract] [Full Text] [Related]
20. Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.
Seu L; Sabbaj S; Duverger A; Wagner F; Anderson JC; Davies E; Wolschendorf F; Willey CD; Saag MS; Goepfert P; Kutsch O
J Virol; 2015 Jul; 89(13):6656-72. PubMed ID: 25878110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
